Creatine deficiency syndrome 2 (CCDS2), also known as guanidinoacetate methyltransferase deficiency, is an autosomal recessive inherited inborn error of metabolism caused by pathogenic variants in the GAMT gene. The alteration prevents normal creatine synthesis and causes the accumulation of guanidinoacetate, a neurotoxic metabolite, with predominant involvement of the central nervous system.
Cerebral creatine deficiency syndrome 2 (GAMT)
The GAMT gene encodes the enzyme guanidinoacetate methyltransferase, responsible for the last step of endogenous creatine synthesis. This reaction transforms guanidinoacetate into creatine by transferring a methyl group from S-adenosylmethionine. Creatine is essential for storing and rapidly mobilizing energy in tissues with high energy demand, especially the brain and muscle. When pathogenic variants exist in GAMT, enzyme activity decreases or disappears, generating a dual pathogenic mechanism: cerebral creatine deficiency and accumulation of guanidinoacetate (GAA), which has a neurotoxic effect. As a consequence, neuronal energy metabolism is altered and progressive neurological symptoms appear. The disease is inherited in an autosomal recessive pattern, meaning the affected individual must inherit two altered copies of the gene, one from each parent. It is a very rare condition, described in a limited number of patients, although likely underdiagnosed. Early diagnosis and treatment are important because they can significantly improve the neurological prognosis.
Symptoms
The onset of CCDS2 usually occurs in early childhood, typically during the first years of life. The main symptoms include global developmental delay, moderate to severe intellectual disability, significant language delay, epilepsy or seizures often difficult to control, movement disorders such as dystonia or choreoathetosis, and behavioral alterations, including autistic traits or hyperactivity. The severity can vary, but without treatment, the progression is usually progressive.
Disease management
Management is based on restoring creatine levels and reducing the production and accumulation of guanidinoacetate. Treatment includes oral creatine supplementation, dietary restriction of arginine or protein, and ornithine administration; in some patients, sodium benzoate may also be used to decrease glycine availability. Epileptic seizures require anticonvulsant treatment and neurological follow-up. Presymptomatic or very early initiation of treatment is associated with better outcomes, so the disease is considered a candidate for newborn screening programs.
Genes analyzed
Bibliography
Goldstein J, Thomas-Wilson A, Groopman E, et al. ClinGen variant curation expert panel recommendations for classification of variants in GAMT, GATM and SLC6A8 for cerebral creatine deficiency syndromes. Mol Genet Metab. 2024 May;142(1):108362.
Sun W, Wu B, Wu M, et al. [Genetic analysis and treatment for an infant with cerebral creatine deficiency syndrome type 2]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020 Sep 10;37(9):1001-1004.
Narayan V, Mahay SB, Verma IC, et al. Case Series of Creatine Deficiency Syndrome due to Guanidinoacetate Methyltransferase Deficiency. Ann Indian Acad Neurol. 2020 May-Jun;23(3):347-351.
